New HIV vaccine trial to start in South Africa

2016-11-27 20:43

(iStock)

Multimedia   ·   User Galleries   ·   News in Pictures Send us your pictures  ·  Send us your stories

Video

In absence of vaccine, best prevention of transmission of HIV is treatment - MSF

2015-12-01 13:49

We speak to Dr. Eric Goemaere from Doctors Without Borders, watch him tell us about the progress South Africa has made when it comes to eradicating HIV.WATCH

Johannesburg — A new vaccine against HIV, to be tested in a trial to be launched in South Africa on Wednesday, could be "the final nail in the coffin" for the disease if it is successful, scientists say.

The study, called HVTN 702, aims to enroll 5 400 sexually active men and women aged between 18 and 35 at 15 sites across South Africa.

It will be the largest and most advanced HIV vaccine clinical trial to take place in South Africa, where more than 1 000 people a day are infected with HIV.

"If deployed alongside our current armoury of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV," Anthony Fauci, director of the US government's National Institute of Allergy and Infectious Diseases (NIAID), said in a statement released ahead of the trial.

"Even a moderately effective vaccine would significantly decrease the burden of HIV disease over time in countries and populations with high rates of HIV infection, such as South Africa," he said.

The vaccine being tested in HVTN 702 is based on a 2009 trial in Thailand that was found to be 31.2% effective at preventing HIV infection over the 3.5 years of follow-up after the vaccination.

The new vaccine aims to provide greater and more sustained protection and has been adapted to the HIV subtype that predominates in southern Africa.

"HIV has taken a devastating toll in South Africa, but now we begin a scientific exploration that could hold great promise for our country," said Glenda Gray, chief executive officer of the South African Medical Research Council.

"If an HIV vaccine were found to work in South Africa, it could dramatically alter the course of the pandemic."

Volunteers for the study, funded by NIAID, are being randomly assigned to receive either the vaccine regimen or a placebo. All participants will receive five injections over a year.

Participants who become infected with HIV in the community will be referred to local medical providers for care and treatment and will be counselled on how to reduce their risk of transmitting the virus.

South Africa has more than 6.8 million people living with HIV, but the country has had remarkable success in rolling out an HIV drug treatment programme, which the government says is the largest in the world.

Life expectancy, which sank as the epidemic grew, has rebounded from 57.1 years in 2009 to 62.9 years in 2014.

Results of the vaccine study are expected in late 2020.

Read more on:    health

Join the conversation!

24.com encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.
NEXT ON NEWS24X

Inside News24

 
/News

Book flights

Compare, Book, Fly

Traffic Alerts
Traffic
There are new stories on the homepage. Click here to see them.
 
English
Afrikaans
isiZulu

Hello 

Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.


Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.

Settings

Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.




Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.